HIV, Hepatitis C Virus (HCV), and Tuberculosis (TB) Drugs, Diagnostics, Vaccines, and Preventive Technologies in Development By Polly Clayden, Simon Collins, Colleen Daniels, Nathan Geffen, Mark Harrington, Richard Jefferys, Coco Jervis, Karyn Kaplan, Erica Lessem, and Tracy Swan.
TAG has previously expressed opposition to the PAVE100A vaccine trial involving the Vaccine Research Center’s DNA and Ad5 candidate(i). With the recent presentation by Dan Barouch of new macaque challenge data involving a DNA/adenovirus prime-boost regimen at the 2009 Keystone meeting(ii), we now must vociferously oppose the proposed descendant of PAVE100A, the HVTN 505 trial.
Over 3,500 people with HIV are on waiting lists for lifesaving antiretroviral drugs. Many more lack access because of other funding cuts and program restrictions. Congress and President Barack Obama must act now to make sure all persons with HIV…
By Mark Harrington On September 30, 2010 the U.S. National Institutes of Health (NIH) became the first research funder to license intellectual property rights to the Medicines Patent Pool essential to manufacturing anti-HIV protease inhibitors. The patent pool is an…
By Coco Jervis and Sue Perez Over the last few years, G8 and other national leaders have lamented that health care systems in poor countries are inadequate to keep pregnant women, mothers, babies, and children healthy and that universal access…
By Richard Jefferys and Scott Morgan In July of this year, the stubborn persistence and commitment of microbicide researchers, advocates, and trial participants was finally rewarded with positive results from a South African trial of the gel form of the…
Slow Implementation for Needed Changes By Sue Perez and Coco Jervis After a century of failed efforts, decades of debate, and months of partisan rancor, this past March, Congress finally passed the Patient Protection and Affordable Care Act of 2010…
By Scott Morgan With no end to the global funding retreat in sight, new strategies are required to change the way we provide treatment to the world's 33 million people infected with HIV. On June 7-10, the Clinton Health Access…
The Making of the HIV Research Catalyst Forum By Lei Chou and Coco Jervis Matt Sharp discusses the quest for a cure. After a five-year hiatus, NATAF (North American AIDS Treatment Action Forum), a community conference focused on HIV treatment…
By Richard Jefferys The CD4 cell count at which combination antiretroviral therapy should be started is a central, unresolved issue in the care of HIV-1-infected patients. -- When to Start Consortium, "Timing of Initiation of Antiretroviral Therapy in AIDS-free HIV-1…